Skip to main content

Table 2 TAs and arsenic speciation of patients and healthy control

From: Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide

 

TAs (ng/g)

iAsIII%

iAsV%

MMA%

DMA%

PMI

SMI

Plasma

 Patients

6.43 ± 1.56

11.40 ± 9.98

44.47 ± 19.81

17.19 ± 13.39

24.50 ± 15.47

0.25 (0–5.04)

1.75 (0.06–37.14)

 Control

8.99 ± 1.14

33.87 ± 18.92

25.26 ± 16.56

19.29 ± 14.53

16.13 ± 13.03

0.28 (0–8.74)

0.82 (0–19.2)

 P value

< 0.001

< 0.001

< 0.001

0.28

< 0.001

0.742

0.002

Urine

 Patients

45.28 ± 33.28

40.08 ± 28.90

8.72 ± 11.42

15.64 ± 14.05

26.36 ± 26.64

0.27 (0–5.52)

1.21 (0–143.01)

 Control

57.55 ± 33.61

1.94 ± 7.19

1.37 ± 6.31

2.49 ± 3.52

78.92 ± 18.79

0.27 (0–1.24)

16.36 (3.32–120.34)

 P value

0.009

< 0.001

< 0.001

< 0.001

< 0.001

0.001

< 0.001

Hair

 Patients

195.43 ± 202.25

29.25 ± 16.44

34.26 ± 20.82

12.05 ± 12.95

18.87 ± 11.95

0.13 (0–2.16)

1.35 (0–91.46)

 Control

198.23 ± 133.16

13.29 ± 26.54

53.00 ± 48.00

14.93 ± 35.01

12.57 ± 26.58

0 (0–0.21)

0 (0–0.01)

 P value

0.96

0.002

0.012

0.558

0.132

0.001

0.007

Nails

 Patients

294.65 ± 158.94

30.21 ± 16.70

32.85 ± 18.08

17.70 ± 12.08

15.72 ± 10.14

0.24 (0–2.64)

0.84 (0–9)

 Control

338.80 ± 212.27

13.64 ± 30.55

20.07 ± 35.56

8.71 ± 26.27

52.57 ± 44.26

0 (0–0.45)

0.35 (0–0.69)

 P value

0.353

0.003

0.034

0.032

< 0.001

0.002

0.514

  1. TAs: total arsenic; iAsIII%: inorganic arsenite/TAs × 100%; iAsV%: inorganic arsenate/TAs × 100%; MMA%: monomethylarsonic acid/TAs × 100%; DMA%: dimethylarsinic acid/TAs × 100%; PMI: primary methylation index; SMI: secondary methylation index